Characterization of Lactobacillus reuteri BCLR-42 and Lactobacillus plantarum BCLP-51 as novel dog probiotics with innate immune enhancing properties

Unlocking the Potential of Probiotics: A Comprehensive Review on Research, Production, and Regulation of Probiotics

This review provides a comprehensive overview of the current state of probiotic research, covering a wide range of topics, including strain identification, functional characterization, preclinical and clinical evaluations, mechanisms of action, therapeutic applications, manufacturing considerations, and future directions. The screening process for potential probiotics involves phenotypic and genomic analysis to identify strains with health-promoting properties while excluding those with any factor that could be harmful to the host. In vitro assays for evaluating probiotic traits such as acid tolerance, bile metabolism, adhesion properties, and antimicrobial effects are described. The review highlights promising findings from in vivo studies on probiotic mitigation of inflammatory bowel diseases, chemotherapy-induced mucositis, dysbiosis, obesity, diabetes, and bone health, primarily through immunomodulation and modulation of the local microbiota in human and animal models. Clinical studies demonstrating beneficial modulation of metabolic diseases and human central nervous system function are also presented. Manufacturing processes significantly impact the growth, viability, and properties of probiotics, and the composition of the product matrix and supplementation with prebiotics or other strains can modify their effects. The lack of regulatory oversight raises concerns about the quality, safety, and labeling accuracy of commercial probiotics, particularly for vulnerable populations. Advancements in multi-omics approaches, especially probiogenomics, will provide a deeper understanding of the mechanisms behind probiotic functionality, allowing for personalized and targeted probiotic therapies. However, it is crucial to simultaneously focus on improving manufacturing practices, implementing quality control standards, and establishing regulatory oversight to ensure the safety and efficacy of probiotic products in the face of increasing therapeutic applications.

Application of Canine-Derived Enterococcus faecium DSM 32820 in Dogs with Acute Idiopathic Diarrhoea

Modulation of the intestinal microbiota through the application of probiotic bacteria is currently one possible way to improve gastrointestinal health in dogs. Knowledge on the efficacy of lactic acid bacteria in a diarrhoeic disorder of dogs is still spreading; however, the used or commercialized strains are often not of canine origin. In this study, E. faecium DSM 32820 strain (a canine isolate selected in our laboratory based on safety and probiotic criteria) was fed to nine dogs suffering from acute non-haemorrhagic diarrhoea at a dose of 1×109 CFU/ml for 7 days. Samples of feces and blood were taken on day 0 and 7. Evaluation of the CIBDAI (Canine Intestinal Bowel Disease activity index) score showed significantly lower vomiting frequency, stool frequency, stool consistency and weight loss at day 7 compared to day 0 (P<0.05). The 16S rRNA gene analysis revealed Firmicutes as the predominant phylum on both sampling days (72.0% vs. 67.9%, day 0 and 7) followed by Proteobacteria (13.4% vs. 6.0%), Actinobacteria (10.0% vs 13.5%), Fusobacteria (4.2% vs. 2.3%) and Bacteroidetes (0.4% vs. 10.4%). The abundance of family Erysipelotrichiaceae was higher on day 7 compared to the initial levels (P<0.05). Among 19 detected fecal enzymatic activities, five (α-chymotrypsin, β-glucuronidase, α-fucosidase, β-galactosidase, N-acetyl-glucosaminidase) were changed (P<0.05). After the application of the DSM 32820 strain, mean fecal dry matter was significantly higher on day 7 compared to baseline (P< 0.05). Although hematological and biochemical parameters in the blood were not significantly different on average, individual values of certain parameters in several dogs were improved.

Effects of Synbiotic Preparation Containing Lactobacillus gasseri BNR17 on Body Fat in Obese Dogs: A Pilot Study

Simple Summary

The present study evaluated the effectiveness of a synbiotic preparation containing L. gasseri BNR17 on body fat in obese dogs. Body weight and the body condition score showed a significant reduction after 10 weeks of synbiotic preparation administration compared with those at baseline (0-week). The subcutaneous fat mass at the level of the third lumbar vertebra and its proportion, compared with the body mass, reduced significantly after 10 weeks of synbiotic preparation administration, compared with those at baseline. Following synbiotic supplementation, microbiome analysis revealed increased microbial diversity, and functional analysis of the microbiota showed an increased abundance of carbohydrate and lipid metabolism. Based on these results, we consider that synbiotic preparation containing L. gasseri BNR17 may play a role in reducing body fat and resolving obesity.

Abstract

Obesity is an important health concern in humans and dogs. It can cause a variety of secondary problems, including low bacterial diversity. Several approaches have been tried to solve this problem; one of them is probiotic supplementation. Lactobacillus gasseri BNR17 is derived from breast milk and has been proven to be effective for obesity in humans. However, there have been no studies using a synbiotic preparation containing L. gasseri BNR17 for obesity management in dogs. Therefore, the present study evaluated the effectiveness of a synbiotic preparation containing L. gasseri BNR17 in reducing body fat in obese dogs. A group of obese dogs were fed a synbiotic preparation for 10 weeks. Obesity variables included body weight, body condition score, subcutaneous fat thickness, subcutaneous fat mass and proportion of the fat mass. In addition, feces collected at 0-week and 10-week time points were analyzed for the intestinal microbiome. Results showed a significant decrease in body weight, body condition score, and subcutaneous fat mass and proportion at the level of the third lumbar vertebra. Diversity and functional analysis of the microbiota in obese dogs showed increased microbial diversity, and increased abundance of metabolism of carbohydrate, and lipid after supplementation with a synbiotic preparation. This study was conducted as a pilot study, and the results demonstrated that a synbiotic preparation containing L. gasseri BNR17 may play a role in reducing body fat and resolving the obesity in dogs.

Search of antimicrobial lactic acid bacteria from Salmonella-negative dogs

Background

Salmonellosis is one of the most important food-borne zoonotic disease affecting both animals and humans. The objective of the present study was to identify gastrointestinal (GI) lactic acid bacteria (LAB) of canine-origin from Salmonella-negative dogs’ faeces able to inhibit monophasic Salmonella Typhimurium previously isolated from dogs’ faeces, in order to be used as a potential probiotic in pet nutrition.

Results

Accordingly, 37 LAB were isolated from Salmonella-negative dogs’ faeces and tested against monophasic S. Typhimurium using the spot on lawn method out of which 7 strains showed an inhibition halo higher than 2.5 cm. These 7 strains were also tested with the co-culture method and one showed the greatest inhibition value (p < 0.05). Subsequently, the isolate was identified through 16S rRNA sequencing and sequence homology and designated as Ligilactobacillus salivarius (L. salivarius). LAB from Salmonella-positive dogs were also identified and none was the selected strain. Finally, to identify the mechanism of inhibition of L. salivarius, the supernatant was analyzed, and a dose response effect was observed.

Conclusions

It is concluded that the canine-origin L. salivarius, could possess some in vitro functional attributes of a candidate probiotic and could prevent monophasic S. Typhimurium colonization or inhibit its activity if the infection occurs.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12917-021-03070-x.

Invited review: Characterization of new probiotics from dairy and nondairy products-Insights into acid tolerance, bile metabolism and tolerance, and adhesion capability

The selection of potential probiotic strains that possess the physiological capacity of performing successfully in the gastrointestinal tract (GIT) is a critical challenge. Probiotic microorganisms must tolerate the deleterious effects of various stresses to survive passage and function in the human GIT. Adhesion to the intestinal mucosa is also an important aspect. Recently, numerous studies have been performed concerning the selection and evaluation of novel probiotic microorganisms, mainly probiotic bacteria isolated from dairy and nondairy products. Therefore, it would be crucial to critically review the assessment methods employed to select the potential probiotics. This article aims to review and discuss the recent approaches, methods used for the selection, and outcomes of the evaluation of novel probiotic strains with the main purpose of supporting future probiotic microbial assessment studies. The findings and approaches used for assessing acid tolerance, bile metabolism and tolerance, and adhesion capability are the focus of this review. In addition, probiotic bile deconjugation and bile salt hydrolysis are explored. The selection of a new probiotic strain has mainly been based on the in vitro tolerance of physiologically related stresses including low pH and bile, to ensure that the potential probiotic microorganism can survive the harsh conditions of the GIT. However, the varied experimental conditions used in these studies (different types of media, bile, pH, and incubation time) hamper the comparison of the results of these investigations. Therefore, standardization of experimental conditions for characterizing and selecting probiotics is warranted.

Evaluation of Weissella Cibaria JW15 Probiotic Derived from Fermented Korean Vegetable Product Supplementation in Diet on Performance Characteristics in Adult Beagle Dog

This study was conducted to evaluate the effects of dietary supplementation of Weissella cibaria JW15 (WJW15) isolated from traditional Korean fermented vegetable product (kimchi) as a probiotic feed additive on nutrient digestibility, blood profiles, feces noxious gas emission, and feces Escherichia coli and Lactobacillus counts in adult Beagle dogs. In total, 15 Beagle dogs with an average initial body weight of 10.20 ± 0.38 kg were randomly assigned into three dietary treatments in a 14-day feeding trial. Dietary treatments consisted of basal diet (CON); MJW = CON + 50 g of WJW15 (3.0 × 108 cfu/g); and BJW = CON + 50 g WJW15 (3.0 × 109 cfu/g). At the end of the experiment, the serum concentration of triglycerides and feces ammonia emissions were decreased (P < 0.05) with the increasing level of WJW15 supplementation. High-density lipoprotein cholesterol in serum and feces lactic acid bacteria count was improved (P < 0.05) with increasing levels of WJW15. In conclusion, WJW15 isolated from kimchi supplementation in adult Beagle dog diet may have beneficial effects as a probiotic feed additive.

Oral administration of bacteriocin-producing and non-producing strains of Enterococcus faecium in dogs

The current effort to incorporate microbial cultures in canine nutrition and thus intake of them on daily base increases our interest in careful and more complex study of their effects in dogs. Many of the commercially used strains have not been tested in dogs and are incorporated only on the base of beneficial effects observed in humans with specific disorders. Moreover, no information on the effects of bacteriocin-producing strains in dogs is available. Therefore, we decided to test and to compare overall effect of bacteriocin non-producing Enterococcus faecium DSM 32820 and enterocin B-producing E. faecium LMG 30881 strain (both of canine origin). Dogs were divided into three treatment groups of ten dogs each: control; DSM 32820 group; and LMG 30881 group, dosing 10⁹ CFU/day/dog. The experiment lasted 35 days with a 14-day treatment period (sample collection at days 0, 7, 14, 35). Despite bacteriocin production is believed that may provide a competitive advantage over neighbouring sensitive strains within shared environment, results indicated somewhat better survival for the DSM 32820 compared to the LMG 30881 group. Furthermore, dogs of DSM 32820 group had optimal faecal consistency throughout the experiment, significantly stimulated phagocytic activity (days 7 and 14) and metabolic burst activity of leukocytes (days 14 and 35) and lower serum glucose concentration (day 35). In contrast, dogs of LMG 30881 group showed higher faecal count of Gram-negative bacteria (day 35), lower haemoglobin and glucose concentration (day 35), and higher metabolic burst activity (days 14 and 35). These results are further evidence of the existence of inter-strain differences in efficacy despite the same origin.